Viwit Pharmaceuticals Limited successfully passed 2nd Mexico COFEPRIS audit

In October of 2016, Viwit Pharmaceuticals Limited successfully completed the 5-day GMP inspection of Mexico COFEPRIS for API Atazanavir Sulfate for the 2nd successive time.

Currently with the global GMP requirements being increasingly strict, this re-inspection is more stringent than ever before. Great challenges, but it's still a great opportunity for Viwit to open to the world. Viwit always adhere to be in compliance with the concept of cGMP standards and commit ourselves to constantly improve the quality management. And successfully, Viwit passed the inspection with excellent performance. "Your production environment and quality system left an excellent impression on us," as the COFEPRIS inspectors said.

Through the COFEPRIS inspection on our GMP, it extremely strengthens our mission to become a global leading pharmaceutical healthcare company. Viwit will continue to adhere to the GMP standards, strictly follow each operation procedure and provide more safe and high quality API products.